CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
The US NIH will share technology with WHO to fight the pandemic
The US National Institutes of Health today committed to sharing several technologies with a World Health Organization body tasked with increasing access to Covid-19...
Will the European Court of Justice put a stop to the evergreening of Truvada...
Truvada, the fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a critical medicine in both HIV treatment and prevention. It is...
FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending...
On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...
Time to put a stop to the abuse of orphan drug regulation- the latest...
Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...
The new EU compulsory licensing regime needs to allow the export of medicines
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London.
A war-weary Ukraine critically depends on the support of...
Why The Request By Least Developed Countries For An Extension Of The Transitional Period...
On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...
It is not too late to solve the know-how problem in the WHO Pandemic...
Introduction
One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...